Bio-IT World June 29, 2022
Funding for single-cell sequencing, small molecule drug discovery, neurological biomarkers, and more.
$245M: Debut Fund for Life Sciences Technology
Biospring Partners, a female-founded and led growth equity firm exclusively focused on B2B life sciences technology companies, announced the closing of its debut fund with north of $245 million in capital commitments from pension plans, fund of funds, endowments, foundations, and family offices. Biospring’s investments are working to push the healthcare industry forward by enabling new forms of biopharma manufacturing, diagnostic testing, and software applications that are fundamentally changing how diseases are researched, diagnosed, and treated.
$60M: Series D Funding for Drug Discovery Robotics
Insilico Medicine, a clinical-stage end-to-end...
Today's Sponsors
Today's Sponsor